DOBUTAMINE INJECTION 12.5 mgml

Riik: Singapur

keel: inglise

Allikas: HSA (Health Sciences Authority)

Toimeaine:

DOBUTAMINE HCl EQV DOBUTAMINE

Saadav alates:

PFIZER PRIVATE LIMITED

ATC kood:

C01CA07

Annus:

12.5 mg/ml

Ravimvorm:

INJECTION

Koostis:

DOBUTAMINE HCl EQV DOBUTAMINE 12.5 mg/ml

Manustamisviis:

INTRAVENOUS

Retsepti tüüp:

Prescription Only

Valmistatud:

HOSPIRA INC

Volitamisolek:

ACTIVE

Loa andmise kuupäev:

1996-02-05

Toote omadused

DOBUTAMINE
INJECTION, USP
FLIPTOP VIAL R
x
only
MUST BE DILUTED PRIOR TO
ADMINISTRATION
_DESCRIPTION _
Dobutamine Injection, USP is a clear, practically colorless, sterile,
nonpyrogenic solution of
dobutamine hydrochloride for intravenous use only. Each milliliter
contains 12.5 mg (41.5
µmol) dobutamine, as the hydrochloride and sodium metabisulfite, 0.2
mg added as antioxidant.
May contain hydrochloric acid and/or sodium hydroxide for pH
adjustment. pH is 3.3 (2.5 to
5.5).
Dobutamine Hydrochloride, USP is chemically designated
(±)-4-[2-[[3-(ρ-hydroxyphenyl)-
1- methylpropyl] amino]ethyl]-
pyrocatechol hydrochloride.
It is a synthetic catecholamine.
Molecular Weight: 337.85
Molecular Formula: C18H23NO3•HCl
_CLINICAL PHARMACOLOGY _
Dobutamine hydrochloride is a direct-acting inotropic agent whose
primary activity results
from
stimulation
of
the
β
receptors
of
the
heart
while
producing
comparatively
mild
chronotropic, hypertensive, arrhythmogenic, and vasodilative effects.
It does not cause the
release
of
endogenous
norepinephrine,
as
does
dopamine.
In
animal
studies,
dobutamine
hydrochloride produces less increase in heart rate and less decrease
in peripheral vascular
resistance for a
_ _
given inotropic effect than does isoproterenol.
In
patients
with
depressed
cardiac
function,
both
dobutamine
hydrochloride
and
isoproterenol increase the cardiac output to a similar degree. In the
case of dobutamine
hydrochloride, this increase is usually not accompanied by marked
increases in heart rate
(although tachycardia is occasionally observed), and the cardiac
stroke volume is usually
increased. In contrast, isoproterenol increases the cardiac index
primarily by increasing the heart
rate while stroke volume changes little or declines.
Facilitation of atrioventricular conduction has been observed in human
electrophysiologic
studies and in patients with atrial fibrillation.
Systemic
vascular
resistance
is
usually
decreased
with
administration
of
dobutamine
hydrochloride. Occasionally, minimum vasoconstriction has been